Reni Benjamin
Stock Analyst at JMP Securities
(1.41)
# 3,545
Out of 5,005 analysts
173
Total ratings
39.86%
Success rate
-14.78%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.33 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $35.65 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.37 | +162.84% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.73 | +174.31% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.69 | +44.13% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $86.85 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.83 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $2.05 | +95.12% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.63 | +145.40% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $5.39 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.23 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.93 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.15 | +10,323.45% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $14.66 | -31.79% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.96 | +26.26% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.57 | +192.58% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $18.10 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $21.43 | +86.65% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.60 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.34 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.47 | +172.11% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.91 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.37 | -14.62% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.27 | +29.67% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.01 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $236.48 | +33.20% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $96.60 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $242.50 | +9.28% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.86 | +249.79% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.53 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $10.43 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.78 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $36.71 | -67.31% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.40 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $35.65
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.37
Upside: +162.84%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.73
Upside: +174.31%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.69
Upside: +44.13%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $86.85
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.83
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $2.05
Upside: +95.12%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.63
Upside: +145.40%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $5.39
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.23
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.93
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.15
Upside: +10,323.45%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $14.66
Upside: -31.79%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.96
Upside: +26.26%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.57
Upside: +192.58%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $18.10
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $21.43
Upside: +86.65%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.60
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.34
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.47
Upside: +172.11%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.91
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.37
Upside: -14.62%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.27
Upside: +29.67%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.01
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $236.48
Upside: +33.20%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $96.60
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $242.50
Upside: +9.28%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.86
Upside: +249.79%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $10.43
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.78
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $36.71
Upside: -67.31%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.40
Upside: -